Literature DB >> 21774789

Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase.

Alexander Pflug1, Taianá Maia de Oliveira, Dirk Bossemeyer, Richard A Engh.   

Abstract

We describe in the present paper mutations of the catalytic subunit α of PKA (protein kinase A) that introduce amino acid side chains into the ATP-binding site and progressively transform the pocket to mimic that of Aurora protein kinases. The resultant PKA variants are enzymatically active and exhibit high affinity for ATP site inhibitors that are specific for Aurora kinases. These features make the Aurora-chimaeric PKA a valuable tool for structure-based drug discovery tasks. Analysis of crystal structures of the chimaera reveal the roles for individual amino acid residues in the binding of a variety of inhibitors, offering key insights into selectivity mechanisms. Furthermore, the high affinity for Aurora kinase-specific inhibitors, combined with the favourable crystallizability properties of PKA, allow rapid determination of inhibitor complex structures at an atomic resolution. We demonstrate the utility of the Aurora-chimaeric PKA by measuring binding kinetics for three Aurora kinase-specific inhibitors, and present the X-ray structures of the chimaeric enzyme in complex with VX-680 (MK-0457) and JNJ-7706621 [Aurora kinase/CDK (cyclin-dependent kinase) inhibitor].

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21774789     DOI: 10.1042/BJ20110592

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  3 in total

1.  A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.

Authors:  Manik Amin; Susan E Minton; Patricia M LoRusso; Smitha S Krishnamurthi; Cheryl A Pickett; Jared Lunceford; Darcy Hille; David Mauro; Mark N Stein; Andrea Wang-Gillam; Lauren Trull; A Craig Lockhart
Journal:  Invest New Drugs       Date:  2015-12-01       Impact factor: 3.850

2.  The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design.

Authors:  Sylvain Couty; Isaac M Westwood; Andrew Kalusa; Celine Cano; Jon Travers; Kathy Boxall; Chiau Ling Chow; Sam Burns; Jessica Schmitt; Lisa Pickard; Caterina Barillari; P Craig McAndrew; Paul A Clarke; Spiros Linardopoulos; Roger J Griffin; G Wynne Aherne; Florence I Raynaud; Paul Workman; Keith Jones; Rob L M van Montfort
Journal:  Oncotarget       Date:  2013-10

3.  Specificity rendering 'hot-spots' for aurora kinase inhibitor design: the role of non-covalent interactions and conformational transitions.

Authors:  Preethi Badrinarayan; G Narahari Sastry
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.